WHO-GMP Certified Facility
ABSOZ DSR
Dual-Action Gastric Motility & Acid Suppression
ABSOZ DSR treats gastroesophageal reflux disease (GERD), acid reflux, heartburn, and indigestion.
DOMPERIDONE
0
MG(Prokinetic)
ESOMEPRAZOLE
0
MG(PPI)
Therapeutic Indications
Precision engineering for comprehensive gastrointestinal patient care
protocols.
GERD & Acid Reflux
Chronic management of
gastroesophageal reflux disease and
associated esophageal damage
through potent acid suppression.
Gastric Motility
Enhancing physiological stomach
emptying to relieve clinical symptoms
of bloating, fullness, and gastric stasis.
Symptomatic Relief
Targeted rapid action against nausea,
vomiting, and dyspepsia through
dopamine receptor antagonism.
Synergistic Gastrointestinal Control
ABSOZ DSR combines two clinically proven agents to address
GI distress from multiple pathways.
Prokinetic Phase: Domperidone serves as a selective dopamine D2 receptor antagonist, facilitating gastric motility and preventing gastric reflux by increasing lower esophageal sphincter tone.
Acid Suppression Phase: Esomeprazole acts as a proton pump inhibitor, specifically inhibiting the H+/K+-ATPase enzyme system at the secretory surface of the gastric parietal cell.
Clinical Cautions
ABSORPTION WARNING
Avoid antacids 2 hours before/after
to ensure optimal absorption.
MEDICAL DISCLOSURE
Tell your doctor if you are pregnant,
breastfeeding, or on other
medications.
SIDE
EFFECTS
Report severe diarrhea, vomiting, or
constipation to your clinician.